STOCK TITAN

Celyad Oncology (CYAD) Stock News, Nov 2023-Sep 2024

CYAD NASDAQ

Celyad Oncology reports corporate, financial, and regulatory news as a biotechnology company focused primarily on unlocking the potential of its intellectual property. Company updates commonly address efforts to partner or out-license selected technologies, asset divestitures such as research-facility equipment and the C-CATHez catheter, and financial results that discuss operating expenses, cash resources, and capital needs.

News releases also cover Belgian transparency notifications, major shareholding thresholds, total voting rights, share counts, double voting rights, and warrants tied to the company’s Euronext-listed securities.

Rhea-AI Summary

Celyad Oncology (Euronext: CYAD) has appointed Matt Kane as its new Chief Executive Officer, effective October 1st, 2024. Kane brings over 20 years of experience in entrepreneurial, CEO, and board roles, with expertise in genome editing and allogeneic CAR T-cell therapies. His career highlights include:

- Raising over $500M in equity financings
- Forming partnerships valued at over $4B
- Co-founding Precision BioSciences (DTIL) in 2006
- Leading Precision's IPO and development of four allogeneic CAR T therapies
- Recent CEO role at Tune Therapeutics, an epigenetic editing company

Kane's appointment aligns with Celyad's focus on CAR T technology and ambitious plans for growth and development in the oncology space.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

Celyad Oncology (CYAD) reported its H1 2024 financial results and business highlights. The company is focusing on research and development, particularly in intellectual property monetization. Key developments include:

1. Proof-of-concept for multiplex shRNA non-gene edited technology and multispecific NKG2D-based CAR T-cell platform.
2. Active participation in scientific conferences and publications in peer-reviewed journals.
3. Re-initiation of C-Cath® manufacturing and commercialization.
4. Cash runway extended until Q3 2025.

Financial highlights:
- R&D expenses: €1.5M (down from €2.1M in H1 2023)
- G&A expenses: €1.7M (down from €3.7M in H1 2023)
- Net loss: €3.0M (€0.07 per share)
- Cash position: €6.2M as of June 30, 2024

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none